Trastuzumab Deruxtecan Scores Two Wins in HER2-Positive Early Breast Cancer

(MedPage Today) — BERLIN — The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different HER2-positive early-stage breast cancer settings in back-to-back randomized clinical trials.
In…

Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118025

Author :

Publish date : 2025-10-19 21:42:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Trastuzumab Deruxtecan Scores Two Wins in HER2-Positive Early Breast Cancer

‘Remarkable’ Survival Outcomes in Cisplatin-Ineligible Bladder Cancer

Where Have All the Obstetricians Gone?

Related Posts

Multiple Viral Infections Alter Stem Cell Transplant Success

Where Have All the Obstetricians Gone?

‘Remarkable’ Survival Outcomes in Cisplatin-Ineligible Bladder Cancer

‘It Could Be Cheap, but It Still Could Be Poison’: What We Heard This Week

OS Win for Enzalutamide in Prostate Cancer at High Risk for Biochemical Recurrence

Could Thymic Health Predict Immunotherapy Outcomes?

Multiple Viral Infections Alter Stem Cell Transplant Success

Where Have All the Obstetricians Gone?

Trastuzumab Deruxtecan Scores Two Wins in HER2-Positive Early Breast Cancer

‘Remarkable’ Survival Outcomes in Cisplatin-Ineligible Bladder Cancer

‘It Could Be Cheap, but It Still Could Be Poison’: What We Heard This Week

OS Win for Enzalutamide in Prostate Cancer at High Risk for Biochemical Recurrence

Could Thymic Health Predict Immunotherapy Outcomes?

Adalimumab Bests Conventional Therapy For Steroid Sparing in Uveitis

Categories

Archives